STK-009

Orthogonal interleukin-2 (IL-2) variant · Synthekine

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for STK-009, covering 2025-04-06 to 2025-11-04. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease [Phase 1]

See pricing